UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2220-7
Program Prior Authorization – Medical Necessity
Medication Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel
P&T Approval Date 10/2020, 3/2021, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Phexxi (lactic acid, citric acid, and potassium bitartrate) vaginal gel is indicated for the
prevention of pregnancy in females of reproductive potential for use as an on-demand method
of contraception. Phexxi is not effective for the prevention of pregnancy when administered
after intercourse.
2. Coverage Criteriaa:
A. Authorization
1. Phexxi will be approved based on all of the following criteria:
a. Used for the prevention of pregnancy
-AND-
b. Patient is unable to use other methods of contraception due to failure, contraindication,
intolerance or refusal. Examples include:
1) Injection (e.g., Depo-Provera)
2) Oral Contraceptive [e.g., norethindrone (generic Micronor), Yaz]
3) Transdermal Patch (e.g. Twirla, Xulane)
4) Vaginal Contraceptive Ring (e.g., Annovera, NuvaRing)
5) Diaphragm
6) Sponge (e.g. Today)
7) Cervical Cap (e.g., FemCap)
8) Female Condom
-AND-
c. History of failure, contraindication, or intolerance to nonoxynol-9 based spermicide
-AND-
d. Provider attests they have counseled the patient regarding a higher rate of pregnancy
prevention with the use of other methods of contraception (e.g., injection, oral
contraception, transdermal patch, vaginal ring) compared to Phexxi
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan
coverage may also impact coverage criteria. Other policies and utilization management programs may
apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Phexxi [package insert]. San Diego, CA: Evofem, Inc; June 2023.
Program Prior Authorization – Medical Necessity Phexxi
Change Control
10/2020 New program.
3/2021 Modified provider attestation statement.
5/2021 Modified provider attestation statement.
5/2022 Annual review. Updated references.
5/2023 Annual review. Updated methods of contraception to examples a
member is unable to use.
5/2024 Annual review. Updated references.
5/2025 Annual review. No changes.
© 2025 UnitedHealthcare Services, Inc.
2